Is Aclaris Therapeutics Stock a Good Investment?
Aclaris Therapeutics Investment Advice | ACRS |
- Examine Aclaris Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Aclaris Therapeutics' leadership team and their track record. Good management can help Aclaris Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Aclaris Therapeutics' business and its evolving consumer preferences.
- Compare Aclaris Therapeutics' performance and market position to its competitors. Analyze how Aclaris Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Aclaris Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Aclaris Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Aclaris Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Aclaris Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Relatively risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Aclaris Therapeutics Stock
Researching Aclaris Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 83.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.7. Some equities with similar Price to Book (P/B) outperform the market in the long run. Aclaris Therapeutics recorded a loss per share of 0.52. The entity had not issued any dividends in recent years.
To determine if Aclaris Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Aclaris Therapeutics' research are outlined below:
| Aclaris Therapeutics generated a negative expected return over the last 90 days | |
| Aclaris Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 31.25 M. Net Loss for the year was (88.48 M) with loss before overhead, payroll, taxes, and interest of (76.91 M). | |
| Aclaris Therapeutics currently holds about 248.6 M in cash with (78.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.73, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Aclaris Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 83.0% of the company shares are held by institutions such as insurance companies |
Aclaris Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Aclaris Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Aclaris Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Aclaris Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 220.46 M.Aclaris Therapeutics' profitablity analysis
The company has Profit Margin (PM) of (1.37) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.23) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $2.23.Determining Aclaris Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Aclaris Therapeutics is a good buy. For example, gross profit margin measures Aclaris Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Aclaris Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Aclaris Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Aclaris Therapeutics. Check Aclaris Therapeutics' Beneish M Score to see the likelihood of Aclaris Therapeutics' management manipulating its earnings.
Basic technical analysis of Aclaris Stock
As of the 26th of February, Aclaris Therapeutics shows the Mean Deviation of 2.86, standard deviation of 3.78, and Risk Adjusted Performance of (0.20). Aclaris Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Aclaris Therapeutics standard deviation and value at risk to decide if Aclaris Therapeutics is priced correctly, providing market reflects its regular price of 2.1 per share. Please also double-check Aclaris Therapeutics jensen alpha, which is currently at (1.06) to validate the company can sustain itself at a future point.Aclaris Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aclaris Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aclaris Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aclaris Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Aclaris Therapeutics' Outstanding Corporate Bonds
Aclaris Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Aclaris Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Aclaris bonds can be classified according to their maturity, which is the date when Aclaris Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Understand Aclaris Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Aclaris Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.20) | |||
| Market Risk Adjusted Performance | (9.87) | |||
| Mean Deviation | 2.86 | |||
| Coefficient Of Variation | (359.65) | |||
| Standard Deviation | 3.78 | |||
| Variance | 14.31 | |||
| Information Ratio | (0.28) | |||
| Jensen Alpha | (1.06) | |||
| Total Risk Alpha | (1.03) | |||
| Treynor Ratio | (9.88) | |||
| Maximum Drawdown | 18.01 | |||
| Value At Risk | (7.95) | |||
| Potential Upside | 5.91 | |||
| Skewness | (0.22) | |||
| Kurtosis | 0.2324 |
| Risk Adjusted Performance | (0.20) | |||
| Market Risk Adjusted Performance | (9.87) | |||
| Mean Deviation | 2.86 | |||
| Coefficient Of Variation | (359.65) | |||
| Standard Deviation | 3.78 | |||
| Variance | 14.31 | |||
| Information Ratio | (0.28) | |||
| Jensen Alpha | (1.06) | |||
| Total Risk Alpha | (1.03) | |||
| Treynor Ratio | (9.88) | |||
| Maximum Drawdown | 18.01 | |||
| Value At Risk | (7.95) | |||
| Potential Upside | 5.91 | |||
| Skewness | (0.22) | |||
| Kurtosis | 0.2324 |
Consider Aclaris Therapeutics' intraday indicators
Aclaris Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Aclaris Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Aclaris Therapeutics time-series forecasting models is one of many Aclaris Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Aclaris Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Aclaris Stock media impact
Far too much social signal, news, headlines, and media speculation about Aclaris Therapeutics that are available to investors today. That information is available publicly through Aclaris media outlets and privately through word of mouth or via Aclaris internal channels. However, regardless of the origin, that massive amount of Aclaris data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Aclaris Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Aclaris Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Aclaris Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Aclaris Therapeutics alpha.
Aclaris Therapeutics Corporate Executives
Elected by the shareholders, the Aclaris Therapeutics' board of directors comprises two types of representatives: Aclaris Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aclaris. The board's role is to monitor Aclaris Therapeutics' management team and ensure that shareholders' interests are well served. Aclaris Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aclaris Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Frank Ruffo | CFO CoFounder | Profile |
Already Invested in Aclaris Therapeutics?
The danger of trading Aclaris Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Aclaris Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Aclaris Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Aclaris Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Aclaris Stock Analysis
When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.